Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 302

1.

Higher expression of EphA2 and ephrin-A1 is related to favorable clinicopathological features in pathological stage I non-small cell lung carcinoma.

Ishikawa M, Miyahara R, Sonobe M, Horiuchi M, Mennju T, Nakayama E, Kobayashi M, Kikuchi R, Kitamura J, Imamura N, Huang CL, Date H.

Lung Cancer. 2012 Jun;76(3):431-8. doi: 10.1016/j.lungcan.2011.12.004. Epub 2012 Jan 10.

PMID:
22236865
2.

Ephrin-A1 inhibits NSCLC tumor growth via induction of Cdx-2 a tumor suppressor gene.

Sukka-Ganesh B, Mohammed KA, Kaye F, Goldberg EP, Nasreen N.

BMC Cancer. 2012 Jul 23;12:309. doi: 10.1186/1471-2407-12-309.

3.

Expression of the receptor tyrosine kinase EphA2 is increased in smokers and predicts poor survival in non-small cell lung cancer.

Brannan JM, Dong W, Prudkin L, Behrens C, Lotan R, Bekele BN, Wistuba I, Johnson FM.

Clin Cancer Res. 2009 Jul 1;15(13):4423-30. doi: 10.1158/1078-0432.CCR-09-0473. Epub 2009 Jun 16.

4.

The clinical significance of EphA2 and Ephrin A-1 in epithelial ovarian carcinomas.

Han L, Dong Z, Qiao Y, Kristensen GB, Holm R, Nesland JM, Suo Z.

Gynecol Oncol. 2005 Nov;99(2):278-86. Epub 2005 Aug 2.

PMID:
16061279
5.

Expression of EphA2 and Ephrin A-1 in carcinoma of the urinary bladder.

Abraham S, Knapp DW, Cheng L, Snyder PW, Mittal SK, Bangari DS, Kinch M, Wu L, Dhariwal J, Mohammed SI.

Clin Cancer Res. 2006 Jan 15;12(2):353-60.

6.

Down-regulation of lysyl oxidase-like 2 (LOXL2) is associated with disease progression in lung adenocarcinomas.

Zhan P, Shen XK, Qian Q, Zhu JP, Zhang Y, Xie HY, Xu CH, Hao KK, Hu W, Xia N, Lu GJ, Yu LK.

Med Oncol. 2012 Jun;29(2):648-55. doi: 10.1007/s12032-011-9959-z. Epub 2011 Apr 26.

PMID:
21519871
7.

Prognostic value of EphA2 and EphrinA-1 in squamous cell cervical carcinoma.

Wu D, Suo Z, Kristensen GB, Li S, Troen G, Holm R, Nesland JM.

Gynecol Oncol. 2004 Aug;94(2):312-9.

PMID:
15297167
8.

Expression of S100A4, ephrin-A1 and osteopontin in non-small cell lung cancer.

Rud AK, Lund-Iversen M, Berge G, Brustugun OT, Solberg SK, Mælandsmo GM, Boye K.

BMC Cancer. 2012 Aug 1;12:333.

9.

[Long-term survival of personalized surgical treatment of locally advanced non-small cell lung cancer based on molecular staging].

Zhou Q, Shi Y, Chen J, Liu B, Wang Y, Zhu D, Zhang HT, Xu P, Gong Y, Chen G, Wei S, Qiu X, Niu Z, Chen X, Lei Z, Duan L, Wu Z.

Zhongguo Fei Ai Za Zhi. 2011 Feb;14(2):86-106. doi: 10.3779/j.issn.1009-3419.2011.02.15. Chinese. Erratum in: Zhongguo Fei Ai Za Zhi. 2011 Jul 20;14(7):592.

10.

Cyclin E is the only cyclin-dependent kinase 2-associated cyclin that predicts metastasis and survival in early stage non-small cell lung cancer.

Müller-Tidow C, Metzger R, Kügler K, Diederichs S, Idos G, Thomas M, Dockhorn-Dworniczak B, Schneider PM, Koeffler HP, Berdel WE, Serve H.

Cancer Res. 2001 Jan 15;61(2):647-53.

11.

Tumor expression of S100A6 correlates with survival of patients with stage I non-small-cell lung cancer.

De Petris L, Orre LM, Kanter L, Pernemalm M, Koyi H, Lewensohn R, Lehtiö J.

Lung Cancer. 2009 Mar;63(3):410-7. doi: 10.1016/j.lungcan.2008.06.003. Epub 2008 Jul 11.

PMID:
18620780
12.

HER-2/neu protein expression and gene alteration in stage I-IIIA non-small-cell lung cancer: a study of 140 cases using a combination of high throughput tissue microarray, immunohistochemistry, and fluorescent in situ hybridization.

Tan D, Deeb G, Wang J, Slocum HK, Winston J, Wiseman S, Beck A, Sait S, Anderson T, Nwogu C, Ramnath N, Loewen G.

Diagn Mol Pathol. 2003 Dec;12(4):201-11.

PMID:
14639106
13.

Higher expression of chemokine receptor CXCR7 is linked to early and metastatic recurrence in pathological stage I nonsmall cell lung cancer.

Iwakiri S, Mino N, Takahashi T, Sonobe M, Nagai S, Okubo K, Wada H, Date H, Miyahara R.

Cancer. 2009 Jun 1;115(11):2580-93. doi: 10.1002/cncr.24281.

14.

Predictive value of EphA2 and EphrinA-1 expression in oesophageal squamous cell carcinoma.

Xu F, Zhong W, Li J, Shanshen Z, Cui J, Nesland JM, Suo Z.

Anticancer Res. 2005 Jul-Aug;25(4):2943-50.

15.

Expression of caveolin-1 is correlated with disease stage and survival in lung adenocarcinomas.

Zhan P, Shen XK, Qian Q, Wang Q, Zhu JP, Zhang Y, Xie HY, Xu CH, Hao KK, Hu W, Xia N, Lu GJ, Yu LK.

Oncol Rep. 2012 Apr;27(4):1072-8. doi: 10.3892/or.2011.1605. Epub 2011 Dec 21.

16.

Overexpression of Pokemon in non-small cell lung cancer and foreshowing tumor biological behavior as well as clinical results.

Zhao ZH, Wang SF, Yu L, Wang J, Chang H, Yan WL, Zhang J, Fu K.

Lung Cancer. 2008 Oct;62(1):113-9. doi: 10.1016/j.lungcan.2008.02.014. Epub 2008 Jun 11.

PMID:
18550205
17.

The diagnostic and prognostic relevance of human telomerase reverse transcriptase mRNA expression detected in situ in patients with nonsmall cell lung carcinoma.

Fujita Y, Fujikane T, Fujiuchi S, Nishigaki Y, Yamazaki Y, Nagase A, Shimizu T, Ohsaki Y, Kikuchi K.

Cancer. 2003 Sep 1;98(5):1008-13.

18.

Lack of ephrin receptor A1 is a favorable independent prognostic factor in clear cell renal cell carcinoma.

Toma MI, Erdmann K, Diezel M, Meinhardt M, Zastrow S, Fuessel S, Wirth MP, Baretton GB.

PLoS One. 2014 Jul 15;9(7):e102262. doi: 10.1371/journal.pone.0102262. eCollection 2014.

19.

EGR1 predicts PTEN and survival in patients with non-small-cell lung cancer.

Ferraro B, Bepler G, Sharma S, Cantor A, Haura EB.

J Clin Oncol. 2005 Mar 20;23(9):1921-6.

20.

Biological markers and DNA flow cytometric analysis in radically resected patients with non-small cell lung cancer. A study of the Perugia Multidisciplinary Team for Thoracic Tumors.

Ludovini V, Pistola L, Gregorc V, Floriani I, Rulli E, Di Carlo L, Semeraro A, Daddi G, Darwish S, Stocchi L, Tofanetti FR, Bellezza G, Sidoni A, Tognellini R, Crinò L, Tonato M.

Tumori. 2008 May-Jun;94(3):398-405.

Items per page

Supplemental Content

Write to the Help Desk